+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Prostaglandin a in plasma of tumor bearing patients

Prostaglandin a in plasma of tumor bearing patients

Periodicum Biologorum 88(1): 25-30

A highly reproducible method of radioimmunossay was applied to assess prostaglandin A (PGA) content in plasma of patients suffering from Hodgkin's disease and breast cancer. Plasma specimens from patients with Hodgkin's disease were collected prior to splenectomy and plasma specimens from women with breast cancer were collected during adjuvant radiotherapy, that is, in the state of minimal residual disease. Elevated values of PGA were detected n plasma of patients suffering from either Hodgkin's disease (802.9 .+-. 120.4 pgml-1) or breast cancer (1212.0 .+-. 0.235.1 pgml-1) while almost normal ranges were observed in plasma of patients with chronic renal failure maintained on regular haemodialysis.

(PDF emailed within 1 workday: $29.90)

Accession: 006206728

Download citation: RISBibTeXText

Related references

Absence of interleukin 1 alpha radioprotection in tumor-bearing animals: elevated plasma levels of prostaglandin E versus a preexisting primed marrow. Journal of Leukocyte Biology 51(1): 53-58, 1992

Tumor host relations 1. increased plasma cortisol in tumor bearing humans compared with patients with benign surgical disease. Journal of Cancer Research and Clinical Oncology 93(3): 281-286, 1979

Prostaglandin E2 and cyclic AMP in tumor and plasma of breast cancer patients. Journal of Cancer Research and Clinical Oncology 102(1): 71-79, 1981

Method of treating tumor-bearing patients with human plasma hyaluronidase. Official Gazette of the United States Patent & Trademark Office Patents 1243(4), Feb 27, 2001

Immune response in tumor-bearing patients and animals. IV. Immunological competence in lymphoid cells of tumor-bearing mice. Revue Europeenne D'etudes Cliniques et Biologiques. European Journal of Clinical and Biological Research 15(1): 90-95, 1970

Anorexia and cachexia in prostaglandin EP1 and EP3 subtype receptor knockout mice bearing a tumor with high intrinsic PGE2 production and prostaglandin related cachexia. Journal of Experimental & Clinical Cancer Research 24(1): 99-107, 2005

Immunohistochemical study of Sertoli-stromal cell tumor; comparison between the tumor arising from the gonad of a testicular feminization syndrome bearing patient and from ovaries of non-bearing patients. Rinsho Byori. Japanese Journal of Clinical Pathology 47(11): 1070-1074, 1999

RNA is more sensitive than DNA in identification of breast cancer patients bearing tumor nucleic acids in plasma. Genes, Chromosomes & Cancer 35(4): 375-376, 2002

Indomethacin therapy abrogates the prostaglandin-mediated suppression of natural killer activity in tumor-bearing mice and prevents tumor metastasis. Cellular Immunology 99(1): 108-118, 1986

Expression of Ia mRNA in tumor-bearing host macrophages Effects of tumor necrosis factor-alpha, lipopolysaccharide, and prostaglandin E-2 on interferon-gamma induction. Virginia Journal of Science 43(2): 272, 1992

Effects of total parenteral nutrition on tumor growth and plasma and tumor free amino acids in tumor bearing rats. Okayama Igakkai Zasshi 94(9-10): 853-876, 1983

Distribution of prostaglandin b prostaglandin e and prostaglandin f series in plasma of cancer patients. Journal of Medicine (Westbury) 12(6): 427-432, 1981

Plasma plasminogen activator in normal subjects before and after venous occlusion and in gynecological tumor bearing patients. Haemostasis 14(1): 138, 1984

Putative transformation dependent proteins in the blood plasma of tumor bearing rats and cancer patients. Cancer Research 42(12): 4964-4969, 1982